Join
Live feed
·
PRReleasevia Quantisnow
Mineralys Therapeutics Inc. logo

Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology's Annual Scientific Session & Expo (ACC.25)

ByQuantisnow·Wall Street's wire, on your screen.
MLYS· Mineralys Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track MLYS (Mineralys Therapeutics Inc.) and more on Quantisnow.